FDA denies accelerated approval for ImmunoGen, Genentech potential breast cancer treatment
FDA denies accelerated approval for ImmunoGen, Genentech potential breast cancer treatment
WALTHAM, Mass. – Federal regulators have ruled that a potential breast cancer treatment from ImmunoGen failed to meet the standard for accelerated approval, the company said Friday.
Read more on Minneapolis-St. Paul Star Tribune